

## MEDIA RELEASE

# Azure Health Technology Limited lodges new Australian Provisional Patent Application on Transmucosal Delivery of Tocotrienols

**Sydney, Australia 7 December 2020** – Azure Health Technology Limited (AZT), the Company commercialising an innovative non-invasive and direct drug and vitamin delivery platform, is pleased to announce that its wholly-owned subsidiary, Invictus Biotechnology Pty Ltd, has lodged a new Provisional Patent Application with IP Australia titled: 'Transmucosal delivery of tocotrienols' (provisional patent application number: [AU2020904488](#)).

This new provisional patent application is directed to compositions formulated for transmucosal delivery of tocotrienols. The original technology for the transmucosal delivery of tocotrienols is described in PCT/AU2013/001310. AZT has now developed improvements to this technology which are specifically focused on the improved transmucosal delivery of tocotrienols as the Active Pharmaceutical Ingredient and improvements in the manufacture of these formulations.

Dr Glenn Tong said "As with most good inventions, with the passage of time (which in this case was almost a decade) and with the benefit of input from various key members of our team such as Dr David Kingston (our Chief Scientific Officer) and Mr Estalella (our President and CEO of Invictus Nutraceuticals, Inc.), there have been some significant improvements to our original technology for the transmucosal delivery of tocotrienols. This new provisional patent application will strengthen the intellectual property rights for both our transmucosal drug candidates which are now entering Phase II clinical studies in NAFLD/NASH and pancreatic cancer as well as our nutraceutical products which are about to be launched in the US and other major markets. Our existing patent estate has granted patents in major markets including the United States, Europe (including the United Kingdom), Japan, China and Australia and we expect the new patent application, once granted, will afford similar protection for AZT. "

For more information please contact:

Dr Glenn Tong  
CEO and Managing Director  
Tel: +61 (0) 412 193 350

Ms Catriona Glover  
Company Secretary  
Tel: +61 (0) 402 328 200

---

### **About Azure Health Technology Limited**

Azure Health Technology Limited (AZT) is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. AZT owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: [www.azureht.com.au](http://www.azureht.com.au)

---